PTP4A3 and gastric neoplasm: We further reproduced the lack of PRL3-minibody therapeutic efficacy in a different orthotopic gastric tumor model using the PRL3+ SNU-484 human gastric cell line (Supplementary Fig. 6c), illustrating that this lack of therapeutic efficacy was not an organ-specific defect.